Amylyx Pharmaceuticals Reports Topline Results From Phase 2 HELIOS Trial Showing Sustained Improvements With AMX0035 In Wolfram Syndrome Patients

Benzinga · 10/17 13:02

Including Enhanced Pancreatic Function And Stabilization Across Secondary Endpoints, With Plans For Phase 3 And FDA Discussions In 2025